Present and Future Roles of FDG-PET/CT Imaging in the Management of Gastrointestinal Cancer: an Update

Overview

Journal Nagoya J Med Sci

Specialty General Medicine

Date 2017 Dec 15

PMID 29238109

Citations 37

Authors

Kazuhiro Kitajima

Masatoyo Nakajo

Hayato Kaida

Ryogo Minamimoto

Kenji Hirata

Masakatsu Tsurusaki

Hiroshi Doi

Yoshiko Ueno

Keitaro Sofue

Yukihisa Tamaki

Koichiro Yamakado

Affiliations

Soon will be listed here.

Abstract

Positron emission tomography/computed tomography (PET/CT) integrated with 2-[F]fluoro-2-deoxy-D-glucose (FDG) is a useful tool for acquisition of both glucose metabolism and anatomic imaging data, as only a single device and one diagnostic session is required, thus opening a new field in clinical oncologic imaging. FDG-PET/CT has been successfully used for initial staging, restaging, assessment of early treatment response, evaluation of metastatic disease response, and prognostication of intestinal cancer as well as various malignant tumors. We reviewed the current status and role of FDG-PET/CT for management of patients with esophageal cancer, gastric cancer, and colorectal cancer, with focus on both its usefulness and limitations.

Citing Articles

Role of Total Body PET/CT in Inflammatory Disorders.

Zoghi S, Mingels C, Badawi R, Spencer B, Yarbrough T, Nardo L Semin Nucl Med. 2024; 55(1):41-51.

PMID: 39578110 PMC: 11645246. DOI: 10.1053/j.semnuclmed.2024.11.001.

A case of mistaken identity: Gallstone-induced hepatic abscess mimicking metastasis.

Kamburoglu M, Buzkan I, Muhtaroglu A, Akdeniz Y, Altintoprak F Ulus Travma Acil Cerrahi Derg. 2024; 30(11):839-841.

PMID: 39498707 PMC: 11843384. DOI: 10.14744/tjtes.2024.28369.

Use of 18-Fluorodeoxyglucose Positron Emission Tomography and Near-Infrared Fluorescence-Guided Imaging Surgery in the Treatment of a Gastric Tumor in a Dog.

Kim S, Chae Y, Kang B, Lee S Animals (Basel). 2024; 14(20).

PMID: 39457847 PMC: 11503833. DOI: 10.3390/ani14202917.

Diagnostic Performance of F-18 FDG PET/CT in the Detection of Recurrent Colorectal Cancer: Correlation with Biochemical Markers and Conventional Imaging Modalities.

Mihailovic J, Roganovic J, Starcevic I, Nikolic I, Prvulovic Bunovic N, Nikin Z J Clin Med. 2024; 13(12).

PMID: 38930131 PMC: 11204678. DOI: 10.3390/jcm13123602.

Impact of FDG-PET/CT and Laparoscopy in Staging of Locally Advanced Gastric Cancer: A Cost Analysis in the Prospective Multicenter PLASTIC-Study.

de Jongh C, van der Meulen M, Gertsen E, Brenkman H, van Sandick J, van Berge Henegouwen M Ann Surg Oncol. 2024; 31(6):4005-4017.

PMID: 38526832 PMC: 11076388. DOI: 10.1245/s10434-024-15103-4.

References

Lee J, Lee M . Positron emission tomography/computed tomography in the staging of colon cancer. Ann Coloproctol. 2014; 30(1):23-7. PMC: 3953165. DOI: 10.3393/ac.2014.30.1.23. View

Goense L, van Rossum P, Reitsma J, Lam M, Meijer G, van Vulpen M . Diagnostic Performance of ¹⁸F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis. J Nucl Med. 2015; 56(7):995-1002. DOI: 10.2967/jnumed.115.155580. View

Maas M, Rutten I, Nelemans P, Lambregts D, Cappendijk V, Beets G . What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis : imaging for recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2011; 38(8):1560-71. PMC: 3126998. DOI: 10.1007/s00259-011-1785-1. View

Pan L, Gu P, Huang G, Xue H, Wu S . Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2009; 21(9):1008-15. DOI: 10.1097/MEG.0b013e328323d6fa. View

Oppedijk V, van der Gaast A, van Lanschot J, van Hagen P, van Os R, van Rij C . Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014; 32(5):385-91. DOI: 10.1200/JCO.2013.51.2186. View

Nakamura R, Obara T, Katsuragawa S, Tamakawa Y, Koeda K, Ikeda K . Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after radiotherapy. Radiat Med. 2002; 20(4):181-6. View

Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A . The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer. 2004; 103(1):148-56. DOI: 10.1002/cncr.20724. View

Hyun S, Choi J, Shim Y, Kim K, Lee S, Cho Y . Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2009; 17(1):115-22. DOI: 10.1245/s10434-009-0719-7. View

Gauthe M, Richard-Molard M, Cacheux W, Michel P, Jouve J, Mitry E . Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Dig Liver Dis. 2015; 47(6):443-54. DOI: 10.1016/j.dld.2015.02.005. View

10.

Malibari N, Hickeson M, Lisbona R . PET/Computed Tomography in the Diagnosis and Staging of Gastric Cancers. PET Clin. 2015; 10(3):311-26. DOI: 10.1016/j.cpet.2015.03.008. View

11.

Njei B, McCarty T, Birk J . Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis. J Gastroenterol Hepatol. 2016; 31(6):1141-6. PMC: 4885788. DOI: 10.1111/jgh.13289. View

12.

Sanli Y, Kuyumcu S, Ozkan Z, Kilic L, Balik E, Turkmen C . The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Ann Nucl Med. 2012; 26(7):551-8. DOI: 10.1007/s12149-012-0609-0. View

13.

Abdalla E, Pisters P . Staging and preoperative evaluation of upper gastrointestinal malignancies. Semin Oncol. 2004; 31(4):513-29. DOI: 10.1053/j.seminoncol.2004.04.014. View

14.

Muijs C, Beukema J, Pruim J, Mul V, Groen H, Plukker J . A systematic review on the role of FDG-PET/CT in tumour delineation and radiotherapy planning in patients with esophageal cancer. Radiother Oncol. 2010; 97(2):165-71. DOI: 10.1016/j.radonc.2010.04.024. View

15.

Malik V, Johnston C, Donohoe C, Claxton Z, Lucey J, Ravi N . (18)F-FDG PET-detected synchronous primary neoplasms in the staging of esophageal cancer: incidence, cost, and impact on management. Clin Nucl Med. 2012; 37(12):1152-8. DOI: 10.1097/RLU.0b013e31827083ba. View

16.

Fendler W, Philippe Tiega D, Ilhan H, Paprottka P, Heinemann V, Jakobs T . Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med. 2013; 54(8):1202-8. DOI: 10.2967/jnumed.112.116426. View

17.

Maffione A, Lopci E, Bluemel C, Giammarile F, Herrmann K, Rubello D . Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review. Eur J Nucl Med Mol Imaging. 2014; 42(1):152-63. DOI: 10.1007/s00259-014-2930-4. View

18.

Langenhoff B, Oyen W, Jager G, Strijk S, Wobbes T, Corstens F . Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol. 2002; 20(22):4453-8. DOI: 10.1200/JCO.2002.12.134. View

19.

Chen S, Hsieh T, Ding H, Yen K, Lin C, Liang J . Pretreatment metabolic tumor volumes to predict the short-term outcome of unresectable locally advanced squamous cell carcinoma of the esophagus treated with definitive chemoradiotherapy. Nucl Med Commun. 2013; 35(3):291-7. DOI: 10.1097/MNM.0000000000000046. View

20.

Cheedella N, Suzuki A, Xiao L, Hofstetter W, Maru D, Taketa T . Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. 2012; 24(5):1262-6. PMC: 3629896. DOI: 10.1093/annonc/mds617. View